Cutting Insurance Eligibility Ups Peds Hospitalization Cost Burden

Share this content:
Cutting Insurance Eligibility Ups Peds Hospitalization Cost Burden
Cutting Insurance Eligibility Ups Peds Hospitalization Cost Burden

FRIDAY, July 13, 2018 (HealthDay News) -- Reducing public insurance (Medicaid and the Children's Health Insurance Program) income eligibility limits would result in large numbers of newly ineligible pediatric hospitalizations, according to a study published online July 9 in Pediatrics.

Jessica L. Bettenhausen, M.D., from the University of Missouri-Kansas City, and colleagues conducted a retrospective cohort study using the 2014 State Inpatient Databases for all pediatric (age, <18) hospitalizations in 14 states. Each patient's zip code was linked to the American Community Survey to ascertain the likelihood of the patient being below three different public insurance income eligibility thresholds (300, 200, and 100 percent of the federal poverty level [FPL]).

The researchers found that reductions in eligibility limits to 300, 200, and 100 percent of the FPL would have resulted in large numbers of newly ineligible hospitalizations (20, 57, and 84 percent of hospitalizations, respectively), corresponding to $1.2, $3.1, and $4.4 billion of estimated child hospitalization costs among 775,460 publicly reimbursed hospitalizations in 14 states. Only slight differences were seen in patient demographics under each eligibility threshold.

"Reducing public insurance eligibility limits would have resulted in numerous pediatric hospitalizations not covered by public insurance, shifting costs to families, other insurers, or hospitals," the authors write. "Without adequately subsidized commercial insurance, this reflects a potentially substantial economic hardship for families and hospitals serving them."

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »